Biodesix
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 45.6m | 54.5m | 38.2m | 49.1m | 71.2m | 89.6m | 111m |
| % growth | 86 % | 20 % | (30 %) | 28 % | 45 % | 26 % | 24 % |
| EBITDA | (21.7m) | (39.3m) | (50.4m) | (35.8m) | (27.6m) | (18.6m) | (<1m) |
| % EBITDA margin | (48 %) | (72 %) | (132 %) | (73 %) | (39 %) | (21 %) | (1 %) |
| Profit | (31.3m) | (43.2m) | (65.4m) | (52.1m) | (45.6m) | (38.3m) | (28.3m) |
| % profit margin | (69 %) | (79 %) | (171 %) | (106 %) | (64 %) | (43 %) | (25 %) |
| EV / revenue | 11.0x | 2.2x | 4.1x | 3.6x | 4.0x | 3.2x | 2.6x |
| EV / EBITDA | -23.1x | -3.1x | -3.1x | -4.9x | -10.3x | -15.3x | -316.1x |
| R&D budget | 10.8m | 12.8m | 13.1m | 10.0m | - | - | - |
| R&D % of revenue | 24 % | 23 % | 34 % | 20 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $8.0m | Series A | |
| N/A | $10.0m | Series B | |
| N/A | $7.1m | Series C | |
| N/A | $20.0m | Series D | |
| N/A | $12.0m | Series D | |
| N/A | $8.8m | Series D | |
| N/A | $8.3m | Series E | |
| N/A | $6.1m | Series E | |
| N/A | $12.0m | Series E | |
| N/A | $11.0m | Series E | |
| N/A | $22.0m | Series F | |
| N/A | $13.2m | Debt | |
| N/A | $5.3m | Debt | |
| N/A | $17.5m | Debt | |
| N/A | $91.0m | IPO | |
$30.0m | Post IPO Debt | ||
* | N/A | $16.3m | Post IPO Equity |
* | N/A | $35.1m | Post IPO Equity |
* | N/A | $55.0m | Private Placement VC |
| Total Funding | CAD246m | ||
Related Content
Recent News about Biodesix
EditBiodesix is a data-driven diagnostic solutions company that leverages state-of-the-art technologies and proprietary artificial intelligence (AI) platforms to discover, develop, and commercialize solutions for clinical unmet needs, primarily focusing on lung disease. The company aims to improve patient outcomes and reduce healthcare costs by providing accurate diagnostic tools that minimize ineffective treatments. Biodesix serves healthcare providers, hospitals, and research institutions, operating within the healthcare diagnostics market. The business model revolves around the development and sale of diagnostic tests, as well as offering related services. Revenue is generated through the sale of these diagnostic tests and partnerships with healthcare providers and research organizations.
Keywords: diagnostic solutions, artificial intelligence, lung disease, patient outcomes, healthcare costs, clinical unmet needs, healthcare providers, hospitals, research institutions, diagnostic tests.
Tech stack
Investments by Biodesix
Edit
